Format

Send to

Choose Destination
Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15.

Cannabidiol as a potential treatment for psychosis.

Author information

1
Tergooi Hospital, Department of Psychiatry, Blaricum, The Netherlands.
2
Brain Center Rudolf Magnus, University Medical Centre Utrecht, Department of Psychiatry, The Netherlands.
3
Department of Psychosis Studies, Institute of Psychiatry, King's College London, UK.
4
Brain Center Rudolf Magnus, University Medical Centre Utrecht, Department of Psychiatry, The Netherlands. Electronic address: m.p.m.boks@umcutrecht.nl.

Abstract

Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if they described experiments with psychosis models, psychotic symptoms or psychotic disorders as outcome measure and involved the use of CBD as intervention. Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment.

KEYWORDS:

Antipsychotics; Cannabidiol; Cannabis; Psychosis; Schizophrenia; Treatment

PMID:
24309088
DOI:
10.1016/j.euroneuro.2013.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center